News Center
NEWS CENTER

Shangke Bio’s NMN raw material has entered the EFSA risk assessment phase, marking a critical step toward market access for NMN in the European Union.


Classification: Company News

Publication:2025-02-11 14:13

Shangke Bio’s Novel Food application for its NMN raw material has officially entered the EFSA risk assessment phase.

According to official information released by the European Commission, Shangke Bio’s NMN raw material has officially entered the EFSA risk‑assessment phase, with an expected completion date of September 2025. Detailed information from the official website is shown in the screenshot below:

Shangke Bio’s NMN raw material received approval as an FDA‑recognized New Dietary Ingredient (NDI) in the United States as early as 2022. In 2024, the company submitted a Novel Food application for its NMN raw material to the European Union and successfully passed EFSA’s preliminary review that same year. This milestone not only marks a significant breakthrough in Shangke Bio’s market entry into the EU but also enhances the prospects of NMN being approved as a novel food ingredient in the region, thereby fostering the industry’s standardized development.

 

What is Novel Food?

According to EU Regulation (EU) 2015/2283, a novel food is any food that was not widely consumed in the European Union prior to 15 May 1997, when the first novel food regulation entered into force.

 

Novel Food includes: newly developed, innovative foods; foods produced using new technologies or processes; and traditional foods originating from third countries outside the European Union.

 

In-house enzymatic process and GMP-compliant manufacturing

Shangke Bio’s NMN raw material is produced using a proprietary enzyme‑based process and manufactured in strict compliance with the GMP (Good Manufacturing Practice) system. To meet rapidly growing market demand, Shangke Bio’s parent company, Zhejiang Shangke Biopharmaceutical Co., Ltd., has built a 230‑mu production facility in Zhejiang dedicated to the manufacture of NAD‑related products and pharmaceuticals, with a designed annual production capacity of 100 tons for NMN raw material.

 

The progress of Shangke Bio’s Novel Food application for NMN raw material not only marks a significant milestone in the company’s internationalization strategy but also injects fresh momentum into the global NMN industry. Moving forward, Shangke Bio will continue to advance the market‑compliant approval and scientific utilization of NMN raw materials worldwide, contributing to the cause of human health.


Leave a Message Online

yzm
Submit